Ad
CTRV - ContraVir Pharmaceuticals Stock Trading
About | ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV)
We are a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus, or VZV.
Quote | ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV)
| Last: | $ |
|---|---|
| Change Percent: | 0.56% |
| Open: | $3.59 |
| Close: | $3.58 |
| High: | $3.70 |
| Low: | $3.53 |
| Volume: | 138,468 |
| Last Trade Date Time: | 07/22/2019 04:54:14 pm |
News | ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV)
-
EDISON, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral i...
-
Introduction: Theory Versus Reality Source Anyone who has run a clinical trial, treated a patient, started a new medical practice, etc., knows that many good ideas are just not as effective in reality as they are on paper- the difference between those ideas and well-executed plans alwa...
Message Board Posts | ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV)
| Subject | By | Source | When |
|---|---|---|---|
| No posts yet. | |||
ContraVir Pharmaceuticals Inc. Company Name:
CTRV Stock Symbol:
NASDAQ Market:
ContraVir Pharmaceuticals Inc. Website:
Ad
-
EDISON, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral i...
-
ContraVir Pharmaceuticals (NASDAQ: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, has closed an underwritten public offering res...
-
EDISON, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral i...